Relistor* (Methylnaltrexone Bromide) — Medicare Part D spending
Salix Pharmaceu* · Rank #320 by total Part D spend · CMS data year 2023
Medicare Part D spent $132,882,335 on Relistor* (Methylnaltrexone Bromide) in 2023, the #320 drug by total Part D spending out of 3,598 drugs. That worked out to about $53.75 per dosage unit, $2,418 per claim and $8,776 per beneficiary, across 54,947 claims for 15,141 beneficiaries. Average spending per dosage unit fell -2.5% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Relistor* (Methylnaltrexone Bromide) spending at a glance (2023)
| Metric | Relistor* (Methylnaltrexone Bromide) |
|---|---|
| Total Part D spending (2023) | $132,882,335 |
| Total spending (2022) | $117,077,748 |
| Year-over-year change in total spending | +13.5% |
| Average spending per dosage unit (2023) | $53.75 |
| Change in spend per dosage unit (YoY) | -2.5% |
| Avg annual change per dosage unit (2019-2023 CAGR) | -2.8% |
| Average spending per claim (2023) | $2,418 |
| Average spending per beneficiary (2023) | $8,776 |
| Total claims (2023) | 54,947 |
| Beneficiaries (2023) | 15,141 |
| Total dosage units (2023) | 4,296,685 |
| Manufacturer(s) | Salix Pharmaceu* |
| National rank by total spend (of 3,598 drugs) | #320 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $117,077,748 | $132,882,335 | +13.5% |
| Avg spend per dosage unit | $55.13 | $53.75 | -2.5% |
| Avg spend per claim | $2,305 | $2,418 | — |
| Avg spend per beneficiary | $8,254 | $8,776 | — |
| Total claims | 50,798 | 54,947 | — |
| Beneficiaries | 14,184 | 15,141 | — |
How Relistor* compares with nearby drugs
Drugs with total Part D spending closest to Relistor* (Methylnaltrexone Bromide):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Relistor* (Methylnaltrexone Bromide) (this drug, #320) | $132,882,335 | $53.75 | -2.5% |
| Epinephrine (#318) | $133,365,359 | $124.71 | -6.8% |
| Prezista (Darunavir) (#319) | $133,001,203 | $60.79 | +6.9% |
| Daptomycin (#321) | $132,869,162 | $56.32 | -30.7% |
| Evrysdi (Risdiplam) (#322) | $132,416,369 | $161.72 | +6.9% |
| Atrovent HFA (Ipratropium Bromide) (#323) | $131,864,275 | $37.36 | +3.9% |
Frequently asked questions
How much does Medicare Part D spend on Relistor*?
Medicare Part D spent $132,882,335 on Relistor* (Methylnaltrexone Bromide) in 2023 (the latest CMS data year), across 54,947 claims for 15,141 beneficiaries. That ranks #320 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Relistor*?
In 2023, the weighted average Medicare Part D spending per dosage unit for Relistor* (Methylnaltrexone Bromide) was $53.75. Compared with 2022 it fell -2.5%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Relistor*?
CMS attributes Relistor* (Methylnaltrexone Bromide) to Salix Pharmaceu* in the 2023 Part D spending file. Average spending per claim was $2,418 and per beneficiary $8,776.
Is the Relistor* figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20